Uncorrelated AltsOps 2026, hosted by Uncorrelated Alts, brings investment managers, allocators and select industry providers to Club 101, 101 Park Avenue in New York City, on Thursday, October 29, 2026, for a full day on fund operations and operational due diligence. Uncorrelated AltsOps 2026 is a B2i Digital (@b2idigital) Featured Conference. See event details at: b2idigital.com/uncorrelated-… The agenda, as of Oct 23, subject to change: 9:45 AM: Attracting Anchor And Early-Stage Investors, with Adam Ross (Abrams Garfinkel & Ross LLP), Jared Fogel (Metalmark Capital) and Scott Sherman (Mesa Lane Capital) 10:30 AM: Allocating To Alternatives Through Private Placement Life Insurance (PPLI) And Private Placement Variable Annuities (PPVA), a registered investment adviser (RIA) panel with David C. Reynolds, CFP®, CLU® (@spearhead), Chad Jaffee, CFP® (Corient), Timothy McCarty (NewEdge Wealth), Adam Sandler, J.D., LL.M. (Cerity Partners) and David Wertentheil (Worth Venture Partners) 11:30 AM: How To Build A Massive Advantage With AI, Angelo Robles, Founder and CEO, SFO Continuity and Billionaire Mastermind 1:00 PM: The Family Office Perspective On Alts, with Angelo Robles, Scott Beechert (Granby Capital Management) and James Nazarov (Nazarov Family Office) 2:00 PM: Investor Insight Tables 2:30 PM: ODD Essentials: What Allocators Look For Before They Invest, with Peter Murrugarra, CAIA, MSIM (Inti Advisors), Stephen Kahn (Talpion Fund Mgmt LP), Eric Lazear (Titan Advisors, LLC) and David Warsoff (J.P. Morgan Alternative Asset Management) 3:15 PM: Wealth Managers And Independent RIAs Allocating To Alts, with Greg Poapst (Fundviews Capital LLC), Lina Botchoukova, CAIA (Lumiere Financial) and Matthew Semino (Global Family Office) 4:15 PM: Partnering With Your Service Providers To Grow Your Fund, with Geoff Marcus (Uncorrelated Alts) and Ishita Shah (Argo Fund Solutions) The day ends with After Alts, evening drinks from 5:30 to 8:30 PM ET with separate registration, subject to host approval. The co-hosts are Dime Commercial Bank, EFSI, Inti Advisors and U-Alts, with EN Capital as Diamond Sponsor. Uncorrelated Alts runs an investment platform for wealth managers, independent RIAs and family offices, provides investment and operational due diligence, and hosts targeted events for alternative strategies, including its flagship Uncorrelated Miami conference. Learn more at uncorrelatedalts.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is a Marketing Partner of Uncorrelated AltsOps 2026, provides marketing support for the event and is not an affiliate of Uncorrelated Alts. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

Calabrese Consulting, LLC, the financial accounting and advisory services firm founded and led by Chief Executive Officer Jenn Calabrese, is a Gold Sponsor of the @NYSE Growth Equity Symposium on Monday, November 30, 2026. The New York Stock Exchange hosts the invitation-only program at 11 Wall Street in collaboration with B2i Digital, bringing NYSE Group listed company executives together with expert advisors and growth-company investors. The symposium is a B2i Digital (@b2idigital) Featured Conference, with event details and invitation requests at: b2idigital.com/nyse-growth-e… From start-up through IPO and into public company reporting, Calabrese Consulting works with private and public companies across a full suite of accounting and advisory services: • IPO and SPAC transactions, along with audit readiness, advisory work and due diligence • SEC financial reporting and Sarbanes-Oxley compliance • Outsourced accounting, plus outsourced CFO and controller services • MWBE certification, plus certification as a Women-Owned Small Business (WOSB) Jenn Calabrese leads the firm alongside Partner and Chief Operating Officer Mike Rollins and Partners Lynn Benoit, Adam Ivezich and Alison Yablonowitz. The program's capital markets sessions for growth companies wrap up with the NYSE Closing Bell viewing and an evening cocktail reception. Learn more about Calabrese Consulting: calabresecpa.com Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital provides marketing support to the NYSE Growth Equity Symposium and is not an affiliate of NYSE. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

Pryor Cashman (@PryorCashman)is a premier, midsized law firm headquartered at 7 Times Square in New York, with offices in Los Angeles and Miami. With its sophisticated securities practice, Pryor Cashman provides public and private companies, financial institutions, investors, and emerging businesses with practical, business-focused counsel across a broad range of complex legal and regulatory matters. The symposium is a B2i Digital (@b2idigital) Featured Conference, with event details and invitation requests at: b2idigital.com/nyse-growth-e… Pryor Cashman's securities and corporate finance practice works with companies raising capital and with the firms that underwrite and place their offerings: • IPOs and uplist transactions, from registration statements and prospectuses to NYSE and @Nasdaq listing applications • Equity and debt offerings, including private placements • Underwriter and placement agent counsel, including due diligence and FINRA compensation filings • Designated Advisor for Disclosure (DAD) and Principal American Liaison (PAL) services for OTCQX companies Headquartered at 7 Times Square in New York, with offices in Los Angeles and Miami, Pryor Cashman also works with foreign issuers entering the U.S. markets through its capital markets team. The day's capital markets sessions wrap up with a view of the @NYSE Closing Bell and a reception that runs into the evening. Learn more about Pryor Cashman: pryorcashman.com Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital provides marketing support to the NYSE Growth Equity Symposium and is not an affiliate of NYSE. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

Algorhythm Holdings, Inc. (@Algorhythm_AI) (@Nasdaq: $RIME), owner of Azure Energy, today reported on a 1,500 MW combined renewable natural gas and biomass power plant project being marketed to potential tenants, including data centers and advanced manufacturing facilities. Algorhythm Holdings, Inc. is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/algorhythm-ho… The project, in which Azure holds a 10% equity stake, will sit on 1,664 acres in north-central Mississippi, with all output delivered behind the meter: • 500 MW of net generation from a biomass pyrolysis-to-power (Azure P2P™) plant and 1,000 MW of natural gas generation • After notice to proceed, the campus is expected to become operational in three phases, reaching approximately 250 MW within 18 months and full generation capacity within 54 months • Azure expects to earn approximately $5 million in fee income in 2027 under the current scope of engagement • The project could be sold upon completion of final permitting in early 2027, with an estimated value of up to $1.66 billion based on prevailing market conditions If sold as valued, Azure's gross proceeds for its equity stake would be approximately $166 million. "Our Mississippi project is large in scale and in the final stage of preparation for market," said Andrew Thompson, CEO of Algorhythm Holdings. Read the full release: globenewswire.com/news-relea… The company expects to select capital markets partners before the end of Q4 2026 to evaluate offers. Algorhythm Holdings, Inc. is a holding company with two primary assets: Azure Holdings and SemiCab Holdings. Azure Energy provides strategic and technical advisory services for renewable biomass power generation infrastructure. Azure launched in 2025 and has already secured equity participation, which management estimates to have a net present value of over $220 million, through multiple power plants under development in the US. Algorhythm Holdings, Inc. also owns and operates SemiCab, an AI-enabled logistics software provider. Since 2020, SemiCab has enabled major retailers, brands, and transportation providers to address common supply-chain problems globally. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted RIME stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

John Passalacqua, Chief Executive Officer of First Phosphate Corp. (@Nasdaq : $PHOS) (CSE: PHOS) (OTCQX: FRSPF) (FSE: KD0), broke down the chemistry of the lithium iron phosphate battery cathode in his presentation at the Precious Metals and Critical Minerals Virtual Investor Conference. By his figures, the LFP cathode is 4% lithium, 35% iron and a full 61% phosphate, and First Phosphate is focused on supplying that phosphate from high-purity igneous rock in Québec. First Phosphate Corp. (@FirstPhosphate) is a New and Notable company in the B2i Digital (@b2idigital ) network. To learn more, visit firstphosphate.com Phosphate's share of the cathode came alongside his figures on the growth of LFP batteries and on the number of companies working in lithium: • LFP batteries now account for 77% of all batteries produced worldwide, up from about 30% market penetration around 2023, by his account • Electric vehicles are only about 15% of the LFP industry, he said, naming large-scale energy storage, AI data centers, robotics and automation, defense and telecom among the biggest growing sectors • He cited 15 times more phosphate than lithium in the cathode of an LFP battery • More than 150 public companies are extracting or purifying in the lithium industry, by his count Passalacqua summed up where First Phosphate sits in that supply chain: "And when we look at phosphate, First Phosphate is the only company, as far as we know, that's out there that's 100% fully focused on phosphate for the lithium iron phosphate battery industry." Watch the full presentation: youtube.com/watch?v=9m-d5k6q… First Phosphate Corp. (NASDAQ: PHOS) (CSE: PHOS) (OTCQX: FRSPF) (FSE: KD0) is a mineral exploration and development and clean technology company dedicated to building and reshoring a vertically integrated mine-to-market supply chain for the production of LFP batteries in North America. Target markets include energy storage, data centers, robotics, mobility, and national security. First Phosphate's flagship Bégin-Lamarche property, located in Saguenay-Lac-Saint-Jean, Québec, Canada, represents a rare North American high-purity igneous phosphate resource of high-purity phosphate characterized by very low levels of impurities. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

Physician paperwork, which Rocket Doctor AI Inc. (@rocketdoctor) (CSE: $AIDR.CN, OTC: AIRDF, Frankfurt: 939) Chief Executive Officer Dr. Essam Hamza put at 20 minutes for every five minutes spent with a patient, set up his case for the company's doctor model at the National Investment Banking Association (NIBA) (@NIBAnet) 153rd Investment Conference in Fort Lauderdale, Florida, on October 7, 2026. The model operates through Rocket Doctor Inc., the wholly owned digital health platform and marketplace subsidiary of Rocket Doctor AI Inc. Rocket Doctor AI Inc. is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/rocket-doctor… As Dr. Hamza laid it out, the platform covers what the doctor needs to practice, where the patients come from and how the company is paid: • On the software side, he listed a suite of software including for onboarding and triage, EMR, decision support system and billing, all supplied to doctors utilizing the platform • Rocket Doctor also runs a patient marketplace for its doctors, which Dr. Hamza said brings the patients to them • The company takes a piece of each visit the doctor completes and does not charge the patient anything, he said, with further fees coming from software sales and from partnerships such as pharmacies On the doctors who join, Dr. Hamza described the arrangement this way: "We've created a situation kind of like an Uber, Shopify model for doctors for the first time. So we've basically been able to empower doctors to be their own entrepreneurs, have a digital storefront, work when they want, where they want, no middleman, full transparency of income." Watch the full presentation: youtu.be/0o2GNoayczk Rocket Doctor AI Inc. delivers physician-guided, AI-powered solutions built to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of its proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide. Alongside the GLM is its digital health platform and marketplace which allows physicians to set up their own virtual practices and to date has helped more than 350 physicians support over 800,000 patient visits across U.S. and Canada. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

Six of seven patients in the final dose cohort of the completed PH-762 Phase 1b trial had a response, Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals Corp. (@phio_pharma)(@Nasdaq :$PHIO ), told the National Investment Banking Association (@NIBAnet) 153rd Investment Conference in Fort Lauderdale, Florida, on October 7, 2026. The trial (NCT 06014086) was designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, an INTASYL® compound, assess the tumor response, and determine the dose or dose range for continued study. Phio Pharmaceuticals Corp. is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/phio-pharmace… Bitterman also took investors through how the trial escalated its dosing, what it found on safety and what was seen at the end of the study: • Twenty-two patients completed treatment across five dose-escalation cohorts, ending with the final cohort of seven • No dose-limiting toxicity was found in any of the five cohorts, Bitterman said, and he described the safety and tolerability profile as very favorable • Bitterman added that no recurrence was seen at the end of the study, which concluded earlier this year On the depth of the responses among those six patients in the final cohort, Bitterman noted: "Four of those six were 100% cancer clear pathologically. One had a greater than 90% clearance as well." Watch the full presentation: youtu.be/9qRhYa1tOCw Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio’s INTASYL compounds are designed to enhance the body’s immune cells to more effectively kill cancer cells. Phio’s lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers. For additional information, visit the Company’s website, phiopharma.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals Corp.(@phio_pharma) (@Nasdaq: $PHIO ), told the National Investment Banking Association (NIBA) 153rd Investment Conference in Fort Lauderdale, Florida, on October 7, 2026, that surgery is today's standard of care for cutaneous squamous cell carcinoma and is very effective, but that there are problems when it comes to dealing with high-risk lesions. PH-762, Phio's lead INTASYL® compound, silences the PD-1 gene and was evaluated ahead of surgical resection in a completed Phase 1b trial. Phio Pharmaceuticals Corp. is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/phio-pharmace… Bitterman set out which lesions are considered high risk and what a tissue-sparing approach aims to do for those patients: • A lesion is considered high risk, he said, based on its size and its placement on the body, and the general health of the patient can also affect it • He described Phio's goal as a tissue-sparing neoadjuvant treatment intended to complement surgery, improve patient outcomes and reduce the surgical burden • Among the goals of the approach, Bitterman also cited the potential to reduce the need for reconstructive surgery Explaining why a tissue-sparing approach is important to patients facing surgery, Bitterman pointed to the effects that typically come with it, saying: "We want to preserve skin integrity. We want to promote faster healing. We want to minimize disfigurement in the form of hypopigmentation and scarring." Watch the full presentation: youtu.be/9qRhYa1tOCw Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio’s INTASYL compounds are designed to enhance the body’s immune cells to more effectively kill cancer cells. Phio’s lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers. For additional information, visit the Company’s website, phiopharma.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

Renforth Resources Inc. (@RenforthRes) (CSE: $RFR.CN | OTC: RFHRF) President and CEO Nicole Brewster wrapped up the prepared portion of her presentation at the Precious Metals & Critical Minerals Virtual Investor Conference on October 15, 2026 by describing the company as two assets with, in her words, a clear path to value. Renforth is advancing the Parbec gold deposit in the prolific Abitibi region of Québec to the point where it can monetize Parbec in order to develop its Victoria nickel focussed bulk tonnage polymetallic deposit. Renforth Resources Inc. is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/renforth-reso… The plan rests on two wholly owned deposits next to Agnico Eagle's Canadian Malartic complex in the Abitibi region of Québec, and on a route for Parbec that Brewster has not yet chosen: • Parbec, an open pit gold deposit on the Cadillac Break, immediately adjacent to Canadian Malartic, one of the largest open-pit gold mines in Canada • Victoria, a Ni/Cu/Co/Zn polymetallic deposit on the company's Malartic Metals Package property, also contiguous to Canadian Malartic • The routes to monetizing Parbec that Brewster listed while saying she cannot yet tell which it will be: bulk sampling for recovery, a small open pit, or a sale or option transaction Setting out the order in which the two assets are meant to advance, Brewster stated: "We will continue to develop the Parbec gold deposit, and we will do so with a view to eventually monetizing it." She closed the point with: "Ultimately, we will monetize Parbec in order to pursue Victoria." Watch the full presentation: youtube.com/watch?v=v04estNh… Renforth Resources Inc. (CSE: RFR | OTC: RFHRF | FSE: 9RR) is a Canadian junior gold and critical minerals resource company focused on advancing the Parbec gold deposit in the prolific Abitibi region of Québec to the point where Renforth can monetize Parbec in order to develop Renforth’s Victoria nickel focussed bulk tonnage polymetallic deposit. Parbec is strategically located immediately adjacent to Agnico Eagle Mines Limited's (TSX: AEM | NYSE: AEM) Canadian Malartic complex, one of the largest open-pit gold mines in Canada. Renforth’s Victoria Ni/Cu/Co/Zn polymetallic deposit is also contiguous to Canadian Malartic, with a resource declared over only 12% of the ~20km length of the mineralized structure, forming part of a wholly owned district scale property with several mineralized occurrences. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

ZenaTech, Inc. (@ZenatechInc) (@Nasdaq : $ZENA) unveiled its proprietary artificial intelligence software suite and planned integration across its Drone as a Service (DaaS) land survey operations. By pairing ZenaDrone high-density LiDAR data acquisition with automated feature extraction and point cloud classification, ZenaTech plans to accelerate survey-grade data delivery time from days to as little as minutes. The AI-powered LiDAR processing is currently in development, with testing across DaaS land surveying, infrastructure monitoring and utility inspection projects expected in 2027. ZenaTech, Inc. is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/zenatech-1 The combined platform is designed to bridge hardware data collection with AI-driven point cloud processing, and its planned capabilities include: • Automated Point Cloud Classification: Designed to use deep learning neural networks to rapidly parse billions of 3D LiDAR points to generate true Digital Terrain Models (DTM) • Automated Feature Extraction and Linework: Computer vision algorithms are intended to detect and vectorize planimetric features and export them directly into CAD and BIM formats • Rapid DaaS Turnaround: The AI software suite is being designed to reduce post-processing workflows by as much as 80% and shorten survey turnaround time Regarding the suite, "Land survey delivery has traditionally been limited by manual post-processing, which caps how many projects a survey team can complete," said Shaun Passley, Ph.D., CEO of ZenaTech. Read the full release: zenatech.com/zenatech-unveil… ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for applications such as agriculture and logistics, as well as ISR, cargo, and counter-UAS for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.